Recent clinical trials in superficial bladder cancer

Area of Science:

• Urology
• Oncology

Background:

• Superficial bladder cancer management literature published since March 2000 is reviewed.
• Current urinary markers for bladder cancer lack specificity or adequate testing.
• Pathological prediction of superficial bladder cancer evolution to invasive disease is an active area of research.

Purpose of the Study:

• To review recent advancements in the management of superficial bladder cancer.
• To assess the efficacy of current diagnostic and prognostic tools.
• To identify promising therapeutic agents and strategies.

Main Methods:

• Literature review of studies published since March 2000.
• Analysis of prognostic factors for recurrence and progression.
• Evaluation of diagnostic techniques like fluorescence detection.
• Assessment of treatment modalities including transurethral resection, bacille Calmette-Guérin, valrubicin, and keyhole limpet haemocyanin.

Main Results:

• No single urinary marker is superior for bladder cancer detection.
• Refined prognostic factors aid in predicting recurrence and progression.
• Transurethral resection completeness is questioned, necessitating repeat procedures for high-grade tumors.
• Fluorescence detection enhances diagnosis and treatment of flat bladder carcinoma.
• Bacille Calmette-Guérin's mechanism requires further study, but long-term therapy may benefit high-risk patients.
• Valrubicin and keyhole limpet haemocyanin show promise as therapeutic agents.

Conclusions:

• Accurate prediction of superficial bladder cancer progression remains challenging.
• Improved diagnostic tools like fluorescence detection are crucial.
• Repeat transurethral resection is vital for high-grade superficial bladder cancer.
• Further research into bacille Calmette-Guérin is needed to optimize its use and minimize side effects.
• Valrubicin and keyhole limpet haemocyanin represent potential new treatment options.